Gertjan Rasschaert/LinkedIn
Mar 1, 2025, 13:01
Gertjan Rasschaert: First patient dosed worldwide today in AZUR4 at UZ Leuven
Gertjan Rasschaert, Medical Doctor and Consultant specializing in Gastrointestinal Oncology and Gastroenterology at UZ Leuven, shared a post on LinkedIn:
“First patient dosed worldwide today in AZUR4 at UZ Leuven.
AZUR-4 is a phase 2, open label, randomized study of neoadjuvant dostarlimab + CAPEOX versus CAPEOX, followed by surgery, in previously untreated locally advanced pMMR/MSS colon cancer.
While the exact relevance of pCR as a surrogate endpoint remains an important question for debate, still, very curious where we will land. Time will tell.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53